Performance summary Business description Business review Governance Financial statements Additional information of the drug.
The size of the class is not yet known.
On 18 July 2012 Diageo settled the claim of the lead claimant Lynette Rowe and agreed a process to consider the remaining claimants in the class.
To enable this process to occur, Lynette Rowe and her legal representatives have agreed not to take any step towards a trial of any issue in the litigation before 31 August 2013.
In the United Kingdom, proceedings have twice been commenced but lapsed for lack of service.
Distillers Company Biochemicals Limited distributed the drug in Australia and the United Kingdom for a period in the late 1950s and early 1960s.
Diageo is unable to quantify meaningfully the possible loss or range of loss to which these lawsuits may give rise.
The company has worked voluntarily for many years with various thalidomide organisations and has provided significant financial support.
f Other The group has extensive international operations and is defendant in a number of legal, customs and tax proceedings incidental to these operations.
There are a number of legal, customs and tax claims against the group, the outcome of which cannot at present be foreseen.
Save as disclosed above, neither Diageo, nor any member of the Diageo group, is or has been engaged in, nor so far as Diageo is aware is there pending or threatened by or against it, any legal or arbitration proceedings which may have a significant effect on the financial position of the Diageo group.
Related party transactions Transactions between the group and its related parties are made on terms equivalent to those that prevail in arms length transactions.
Subsidiaries Transactions between the company and its subsidiaries are eliminated on consolidation and therefore are not disclosed.
Details of the principal group companies are given after these financial statements.
Associates and joint ventures Sales and purchases to and from associates and joint ventures are principally in respect of premium drinks products but also include the provision of management services.
All transactions are on terms equivalent to those in an arms length transaction.
2012 2011 2010 million million million Income statement items Sales to associates 37 46 74 Purchases from associates 22 26 27 Sales to joint ventures 5 5 5 Purchases from joint ventures 41 21 17 Balance sheet items Group payables to associates 1 8 9 Group receivables from associates 2 2 Loans receivable from associates 57 63 57 Group payables to joint ventures 1 3 2 Group receivables from joint ventures 3 7 7 Cash flow items Loans and equity contribution to associates 27 22 64 Including purchase of maturing inventories from Mot Hennessy of 9 million 2011 9 million: 2010 8 million.
Other disclosures in respect of associates are included in note 7 and note 14.
Key management personnel The key management of the group comprises the executive and non-executive directors, the members of the executive committee and the company secretary.
They are listed under Board of directors and executive committee.
2012 2011 2010 million million million Salaries and short term employee benefits 18 20 21 Non-executive directors fees 1 1 1 Share-based payments 9 10 10 Post employment benefits 1 4 4 Termination benefits 1 29 36 36 Non-executive directors do not receive share-based payments or post employment benefits.
Details are given in the directors remuneration report of the individual directors remuneration and transactions between the group and key management personnel.
Pension plans The Diageo pension plans are recharged with the cost of administration services provided by the company to the pension plans and with professional fees paid by the company on behalf of the pension plans.
The total amount recharged for the year was 10 million 2011 18 million: 2010 28 million.
Notes to the consolidated financial statements 171
